http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111333614-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 |
| filingDate | 2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111333614-B |
| titleOfInvention | Quinolinone compounds and use thereof |
| abstract | The application discloses quinolinone compounds containing rhodanine and similar fragments thereof and pharmaceutically acceptable salts thereof, which are shown in a general formula I in the technical field of organic chemistry. Wherein, the substituent R 1 、X、R 2 Have the meanings given in the description. The invention also relates to the application of the compound of the general formula I and the pharmaceutically acceptable salt thereof in the preparation of medicines for treating diseases caused by abnormal expression of IDO, in particular to the application in the preparation of medicines for treating and/or preventing cancers. |
| priorityDate | 2020-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.